Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Neurological Disorder Drugs market report explains the definition, types, applications, major countries, and major players of the Neurological Disorder Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Boehringer Ingelheim GmbH
AstraZeneca
Merck & Co
GlaxoSmithKline plc
Teva Pharmaceutical
Bayer AG
Novartis AG
By Type:
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
By End-User:
Hospital
Clinic
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Neurological Disorder Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Neurological Disorder Drugs Outlook to 2028- Original Forecasts
-
2.2 Neurological Disorder Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Neurological Disorder Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Neurological Disorder Drugs Market- Recent Developments
-
6.1 Neurological Disorder Drugs Market News and Developments
-
6.2 Neurological Disorder Drugs Market Deals Landscape
7 Neurological Disorder Drugs Raw Materials and Cost Structure Analysis
-
7.1 Neurological Disorder Drugs Key Raw Materials
-
7.2 Neurological Disorder Drugs Price Trend of Key Raw Materials
-
7.3 Neurological Disorder Drugs Key Suppliers of Raw Materials
-
7.4 Neurological Disorder Drugs Market Concentration Rate of Raw Materials
-
7.5 Neurological Disorder Drugs Cost Structure Analysis
-
7.5.1 Neurological Disorder Drugs Raw Materials Analysis
-
7.5.2 Neurological Disorder Drugs Labor Cost Analysis
-
7.5.3 Neurological Disorder Drugs Manufacturing Expenses Analysis
8 Global Neurological Disorder Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Neurological Disorder Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Neurological Disorder Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Neurological Disorder Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Neurological Disorder Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Antipsychotic Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Hypnotic & Sedative Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Analgesics Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Anticoagulants Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Neurological Disorder Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Neurological Disorder Drugs Market Analysis and Outlook till 2022
-
10.1 Global Neurological Disorder Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Neurological Disorder Drugs Consumption (2017-2022)
-
10.2.2 Canada Neurological Disorder Drugs Consumption (2017-2022)
-
10.2.3 Mexico Neurological Disorder Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.2 UK Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.3 Spain Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.4 Belgium Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.5 France Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.6 Italy Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.7 Denmark Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.8 Finland Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.9 Norway Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.10 Sweden Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.11 Poland Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.12 Russia Neurological Disorder Drugs Consumption (2017-2022)
-
10.3.13 Turkey Neurological Disorder Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.2 Japan Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.3 India Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.4 South Korea Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.8 Thailand Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.9 Singapore Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.11 Philippines Neurological Disorder Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Neurological Disorder Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Neurological Disorder Drugs Consumption (2017-2022)
-
10.5.2 Colombia Neurological Disorder Drugs Consumption (2017-2022)
-
10.5.3 Chile Neurological Disorder Drugs Consumption (2017-2022)
-
10.5.4 Argentina Neurological Disorder Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Neurological Disorder Drugs Consumption (2017-2022)
-
10.5.6 Peru Neurological Disorder Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Neurological Disorder Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Neurological Disorder Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Neurological Disorder Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Neurological Disorder Drugs Consumption (2017-2022)
-
10.6.3 Oman Neurological Disorder Drugs Consumption (2017-2022)
-
10.6.4 Qatar Neurological Disorder Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Neurological Disorder Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Neurological Disorder Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Neurological Disorder Drugs Consumption (2017-2022)
-
10.7.2 South Africa Neurological Disorder Drugs Consumption (2017-2022)
-
10.7.3 Egypt Neurological Disorder Drugs Consumption (2017-2022)
-
10.7.4 Algeria Neurological Disorder Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Neurological Disorder Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Neurological Disorder Drugs Consumption (2017-2022)
11 Global Neurological Disorder Drugs Competitive Analysis
-
11.1 Boehringer Ingelheim GmbH
-
11.1.1 Boehringer Ingelheim GmbH Company Details
-
11.1.2 Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Boehringer Ingelheim GmbH Neurological Disorder Drugs Main Business and Markets Served
-
11.1.4 Boehringer Ingelheim GmbH Neurological Disorder Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 AstraZeneca
-
11.2.1 AstraZeneca Company Details
-
11.2.2 AstraZeneca Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 AstraZeneca Neurological Disorder Drugs Main Business and Markets Served
-
11.2.4 AstraZeneca Neurological Disorder Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Merck & Co
-
11.3.1 Merck & Co Company Details
-
11.3.2 Merck & Co Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Merck & Co Neurological Disorder Drugs Main Business and Markets Served
-
11.3.4 Merck & Co Neurological Disorder Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 GlaxoSmithKline plc
-
11.4.1 GlaxoSmithKline plc Company Details
-
11.4.2 GlaxoSmithKline plc Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 GlaxoSmithKline plc Neurological Disorder Drugs Main Business and Markets Served
-
11.4.4 GlaxoSmithKline plc Neurological Disorder Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Teva Pharmaceutical
-
11.5.1 Teva Pharmaceutical Company Details
-
11.5.2 Teva Pharmaceutical Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Teva Pharmaceutical Neurological Disorder Drugs Main Business and Markets Served
-
11.5.4 Teva Pharmaceutical Neurological Disorder Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Bayer AG
-
11.6.1 Bayer AG Company Details
-
11.6.2 Bayer AG Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Bayer AG Neurological Disorder Drugs Main Business and Markets Served
-
11.6.4 Bayer AG Neurological Disorder Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Novartis AG
-
11.7.1 Novartis AG Company Details
-
11.7.2 Novartis AG Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Novartis AG Neurological Disorder Drugs Main Business and Markets Served
-
11.7.4 Novartis AG Neurological Disorder Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
12 Global Neurological Disorder Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Neurological Disorder Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Antipsychotic Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Hypnotic & Sedative Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Analgesics Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Anticoagulants Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Neurological Disorder Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Neurological Disorder Drugs Market Analysis and Outlook to 2028
-
13.1 Global Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Neurological Disorder Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Neurological Disorder Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Neurological Disorder Drugs
-
Figure of Neurological Disorder Drugs Picture
-
Table Global Neurological Disorder Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Neurological Disorder Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Antipsychotic Consumption and Growth Rate (2017-2022)
-
Figure Global Hypnotic & Sedative Consumption and Growth Rate (2017-2022)
-
Figure Global Analgesics Consumption and Growth Rate (2017-2022)
-
Figure Global Anticoagulants Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Neurological Disorder Drugs Consumption by Country (2017-2022)
-
Table North America Neurological Disorder Drugs Consumption by Country (2017-2022)
-
Figure United States Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Neurological Disorder Drugs Consumption by Country (2017-2022)
-
Figure Germany Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Neurological Disorder Drugs Consumption by Country (2017-2022)
-
Figure China Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Neurological Disorder Drugs Consumption by Country (2017-2022)
-
Figure Brazil Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Neurological Disorder Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Neurological Disorder Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Neurological Disorder Drugs Consumption by Country (2017-2022)
-
Figure Australia Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Neurological Disorder Drugs Consumption and Growth Rate (2017-2022)
-
Table Boehringer Ingelheim GmbH Company Details
-
Table Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim GmbH Neurological Disorder Drugs Main Business and Markets Served
-
Table Boehringer Ingelheim GmbH Neurological Disorder Drugs Product Portfolio
-
Table AstraZeneca Company Details
-
Table AstraZeneca Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Neurological Disorder Drugs Main Business and Markets Served
-
Table AstraZeneca Neurological Disorder Drugs Product Portfolio
-
Table Merck & Co Company Details
-
Table Merck & Co Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck & Co Neurological Disorder Drugs Main Business and Markets Served
-
Table Merck & Co Neurological Disorder Drugs Product Portfolio
-
Table GlaxoSmithKline plc Company Details
-
Table GlaxoSmithKline plc Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline plc Neurological Disorder Drugs Main Business and Markets Served
-
Table GlaxoSmithKline plc Neurological Disorder Drugs Product Portfolio
-
Table Teva Pharmaceutical Company Details
-
Table Teva Pharmaceutical Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Neurological Disorder Drugs Main Business and Markets Served
-
Table Teva Pharmaceutical Neurological Disorder Drugs Product Portfolio
-
Table Bayer AG Company Details
-
Table Bayer AG Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer AG Neurological Disorder Drugs Main Business and Markets Served
-
Table Bayer AG Neurological Disorder Drugs Product Portfolio
-
Table Novartis AG Company Details
-
Table Novartis AG Neurological Disorder Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis AG Neurological Disorder Drugs Main Business and Markets Served
-
Table Novartis AG Neurological Disorder Drugs Product Portfolio
-
Figure Global Antipsychotic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hypnotic & Sedative Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Analgesics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Anticoagulants Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Neurological Disorder Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Neurological Disorder Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Neurological Disorder Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Neurological Disorder Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Neurological Disorder Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Neurological Disorder Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Neurological Disorder Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Neurological Disorder Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Neurological Disorder Drugs Consumption Forecast and Growth Rate (2022-2028)
-
